AGXT

AGXT

The AGXT gene encodes the enzyme alanine-glyoxylate aminotransferase, which is primarily expressed in the liver. This enzyme plays a crucial role in the detoxification of glyoxylate, a byproduct of metabolism, by converting it into glycine. Mutations in the AGXT gene can lead to a rare genetic disorder known as primary hyperoxaluria type 1 (PH1), characterized by the overproduction of oxalate, leading to kidney stones and renal failure.

Structure and Function

The AGXT gene is located on chromosome 2q37.3 and consists of 11 exons. The enzyme alanine-glyoxylate aminotransferase is a pyridoxal phosphate-dependent enzyme that catalyzes the transamination reaction between glyoxylate and L-alanine to produce glycine and pyruvate. This reaction is essential for the detoxification of glyoxylate, preventing its conversion to oxalate.

Clinical Significance

Mutations in the AGXT gene are responsible for primary hyperoxaluria type 1 (PH1), an autosomal recessive disorder. PH1 is characterized by the excessive production of oxalate, which combines with calcium to form calcium oxalate stones in the kidneys and urinary tract. Over time, this can lead to kidney damage and end-stage renal disease.

Diagnosis

Diagnosis of PH1 typically involves genetic testing to identify mutations in the AGXT gene. Biochemical tests may also be conducted to measure oxalate levels in the urine and plasma.

Treatment

Management of PH1 includes high fluid intake, dietary modifications, and medications to reduce oxalate production. In severe cases, liver transplantation may be necessary, as the liver is the primary site of AGXT expression and activity.

Genetic Variants

Several mutations in the AGXT gene have been identified, including missense, nonsense, and splice-site mutations. The most common mutation in Caucasian populations is the c.508G>A (p.Gly170Arg) mutation, which affects the enzyme's stability and function.

Research and Future Directions

Research is ongoing to develop gene therapy and other novel treatments for PH1. Understanding the molecular mechanisms of AGXT mutations and their effects on enzyme function is crucial for developing targeted therapies.

Also see

• Primary hyperoxaluria
• Kidney stones
• Liver transplantation
• Genetic testing